David Lee Johnson - Apr 1, 2022 Form 4 Insider Report for Global Blood Therapeutics, Inc. (GBT)

Role
Chief Commercial Officer
Signature
/s/ Miguel Carrillo, Attorney-in-Fact
Stock symbol
GBT
Transactions as of
Apr 1, 2022
Transactions value $
-$54,332
Form type
4
Date filed
4/5/2022, 07:00 PM
Previous filing
Mar 3, 2022
Next filing
May 12, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction GBT Common Stock Options Exercise +4.38K +9.6% 49.9K Apr 1, 2022 Direct F1
transaction GBT Common Stock Tax liability -$54.3K -1.51K -3.03% $35.91 48.4K Apr 1, 2022 Direct F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction GBT Restricted Stock Units Options Exercise $0 -4.38K -100% $0.00* 0 Apr 1, 2022 Common Stock 4.38K Direct F1, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each Restricted Stock Unit ("RSU") represents the right to receive one share of the Issuer's Common Stock.
F2 Represents the number of shares of the Issuer's Common Stock withheld to satisfy the Reporting Person's tax obligations in connection with the vesting of 4,375 shares of Common Stock underlying the Reporting Person's RSUs.
F3 The shares of Common Stock underlying the RSUs vested with respect to 1/4th of the underlying shares on April 1, 2019, and with respect to 1/6th of the remaining underlying shares on a semi-annual basis thereafter through April 1, 2022.